Stockscreener 앱 받기
4.23
7.24%
-0.33
시장 영업 전:
4.24
0.010
+0.24%
전일 마감가:
$4.56
열려 있는:
$4.53
하루 거래량:
1.07M
Relative Volume:
0.54
시가총액:
$281.40M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-4.5484
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
-0.24%
1개월 성능:
+24.05%
6개월 성능:
+76.99%
1년 성능:
+153.29%
1일 변동 폭
$4.16
$4.60
1주일 범위
$4.12
$4.99
52주 변동 폭
$1.66
$6.42
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
4.23 | 281.40M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Cardiff Oncology to Present at Upcoming Investor Conferences - The Manila Times
Can Cardiff Oncology's New Colorectal Cancer Approach Transform Treatment? CEO to Reveal Strategy - StockTitan
Critical Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR) - Defense World
Cardiff Oncology (CRDF) to Release Earnings on Thursday - Defense World
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - The Manila Times
Can Cardiff Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Simply Wall St
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short Interest - MarketBeat
Taking on analysts’ expectations and winning: Cardiff Oncology Inc (CRDF) - SETE News
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Increase in Short Interest - Defense World
SG Americas Securities LLC Sells 6,103 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World
Cardiff Oncology Inc (CRDF) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Cardiff Oncology Inc (CRDF) produces promising results - US Post News
Metastatic Prostate Cancer Clinical and Non-Clinical Studies, - openPR
Cardiff Oncology Inc (CRDF) Beta Value: Understanding the Market Risk - The News Heater
Get in on Cardiff Oncology Inc’s (CRDF) buy-in window today! - SETE News
Cardiff Oncology Inc (CRDF) Stock: A Year of Stock Market Dynamics - The InvestChronicle
BlackRock, Inc. Expands Stake in Cardiff Oncology Inc. - GuruFocus.com
Quarterly Snapshot: Quick and Current Ratios for Cardiff Oncology Inc (CRDF) - The Dwinnex
Analysts review Cardiff Oncology Inc’s rating - Knox Daily
Cardiff Oncology Inc (CRDF)’s results reveal risk - US Post News
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
HB Wealth Management LLC Invests $105,000 in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Assenagon Asset Management S.A. Sells 203,292 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Cardiff Oncology, Inc. (NASDAQ:CRDF) Position Boosted by Barclays PLC - Defense World
If You Don’t Buy Cardiff Oncology Inc (NASDAQ: CRDF) Now, You’ll Kick Yourself Later - Stocks Register
Jane Street Group LLC Cuts Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 39,542 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology updates bylaws, changes fiscal year - Investing.com India
Cardiff Oncology Inc (NASDAQ: CRDF) Is A Buzzing Hot Stock - Stocks Register
Cardiff Oncology updates bylaws, changes fiscal year By Investing.com - Investing.com South Africa
State Street Corp Purchases 27,628 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 21.6% - MarketBeat
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Institutions along with individual investors who hold considerable shares inCardiff Oncology, Inc. (NASDAQ:CRDF) come under pressure; lose 27% of holdings value - Simply Wall St
While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownership - Yahoo Finance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Cardiff Oncology CFO James Levine purchases $36,725 in shares By Investing.com - Investing.com Canada
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update - MarketBeat
Piper Sandler Boosts Cardiff Oncology (NASDAQ:CRDF) Price Target to $10.00 - Defense World
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
Cardiff Oncology price target raised to $10 from $7 at Piper Sandler - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
0.33%
자본화:
|
볼륨(24시간):